Patents by Inventor Martin P. Vacanti
Martin P. Vacanti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11028363Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: June 18, 2018Date of Patent: June 8, 2021Assignee: VCELL THERAPEUTICS, INC.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20210060163Abstract: A method has been developed to enhance the efficacy of cancer vaccines by activating the immune system against a greater variety of antigens expressed in the tumor cells. In this modification, the vaccine is created against not only the more mature cancer cells, but also cancer stem cells (CSCs), that act as tumor propagating cells, and can also be made against as the more mature progeny of the CSCs that are normally present within the malignant tumors in numbers which are too low to effectively manufacture a vaccine against their antigens, but which are responsible for recurrence of the malignant tumor. These include pluripotent and stem cells induced from cells in a tumor biopsy by exposure to stress inducing agents that cause the cells to almost die, thereby causing cells to de-differentiate. The method greatly increases the variety of the tumor antigens at which the vaccine is targeted.Type: ApplicationFiled: September 3, 2020Publication date: March 4, 2021Inventors: Charles A. Vacanti, Martin P. Vacanti
-
Publication number: 20190060373Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: June 18, 2018Publication date: February 28, 2019Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 9999638Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: September 22, 2016Date of Patent: June 19, 2018Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 9663765Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: September 4, 2015Date of Patent: May 30, 2017Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20170007647Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: September 22, 2016Publication date: January 12, 2017Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20150376576Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: September 4, 2015Publication date: December 31, 2015Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 9145545Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: September 12, 2013Date of Patent: September 29, 2015Assignee: VBI Technologies, LLCInventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20150110749Abstract: The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.Type: ApplicationFiled: April 24, 2013Publication date: April 23, 2015Inventors: Charles A. Vacanti, Martin P. Vacanti, Koji Kojima, Haruko Obokata, Teruhiko Wakayama, Yoshiki Sasai, Masayuki Yamato
-
Publication number: 20140017708Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: September 12, 2013Publication date: January 16, 2014Applicant: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 8551775Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: November 11, 2010Date of Patent: October 8, 2013Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20110281282Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: ApplicationFiled: November 11, 2010Publication date: November 17, 2011Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 7964394Abstract: Highly undifferentiated spore-like cells can be isolated from many different tissues and bodily fluids and used to treat a wide variety of disorders.Type: GrantFiled: July 17, 2009Date of Patent: June 21, 2011Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Publication number: 20100009440Abstract: Highly undifferentiated spore-like cells can be isolated from many different tissues and bodily fluids and used to treat a wide variety of disorders.Type: ApplicationFiled: July 17, 2009Publication date: January 14, 2010Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 7575921Abstract: Highly undifferentiated spore-like cells can be isolated from many different tissues and bodily fluids and used to treat a wide variety of disorders.Type: GrantFiled: June 13, 2003Date of Patent: August 18, 2009Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 7560275Abstract: Compositions and methods for growing new skin, which can be used to repair or replace skin that has been damaged or removed by a variety of insults.Type: GrantFiled: March 3, 2003Date of Patent: July 14, 2009Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 7470425Abstract: The invention features a method for generating new tissue by obtaining a liquid hydrogel-cell composition including a hydrogel and tissue precursor cells; delivering the liquid hydrogel-cell composition into a permeable, biocompatible support structure; and allowing the liquid hydrogel-cell composition to solidify within the support structure and the tissue precursor cells to grow and generate new tissue. The invention also features a tissue forming structure including a permeable, biocompatible support structure having a predetermined shape that corresponds to the shape of desired tissue; and a hydrogel-cell composition at least partially filling the support structure, wherein the hydrogel-cell composition includes a hydrogel and tissue precursor cells. The new tissue forming structure can be used in new methods to generate various tissues (e.g., to treat defective tissue) including new bone, cartilage, and nervous tissue such as spinal cord tissue. The invention also new isolated nervous system stem cells.Type: GrantFiled: November 14, 2003Date of Patent: December 30, 2008Assignees: VBI Technologies, L.L.C., The Children's Medical Center CorporationInventors: Charles A. Vacanti, Joseph P. Vacanti, Martin P. Vacanti
-
Patent number: 7319035Abstract: The invention provides methods of generating a natural, living biological matrix that can serve as, or form a part of, a natural biological scaffold. The matrix is generated by incubating together biological cells and cellular debris. Any naturally occurring cell can be a biological cell included in the matrix. The invention also provides methods of treating a patient by implanting the matrix or scaffolding into a tissue of the patient, thereby augmenting the existing tissue.Type: GrantFiled: October 17, 2003Date of Patent: January 15, 2008Assignee: VBI Technologies, L.L.C.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 7060492Abstract: Highly undifferentiated spore-like cells can be isolated from many different tissues and bodily fluids after those tissues and fluids have been exposed to extreme conditions. The spore-like cells can be used to treat a wide variety of disorders.Type: GrantFiled: March 3, 2004Date of Patent: June 13, 2006Assignee: VBI Technologies, L.L.C.Inventors: Charles A. Vacanti, Martin P. Vacanti
-
Publication number: 20040175823Abstract: Highly undifferentiated spore-like cells can be isolated from many different tissues and bodily fluids after those tissues and fluids have been exposed to extreme conditions. The spore-like cells can be used to treat a wide variety of disorders.Type: ApplicationFiled: March 3, 2004Publication date: September 9, 2004Inventors: Charles A. Vacanti, Martin P. Vacanti